Monopar Therapeutics (MNPR) Competitors $25.79 -0.03 (-0.12%) (As of 11:16 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends MNPR vs. PHAT, PROK, ANNX, DNA, ATXS, HUMA, PRTC, ANAB, MREO, and CRMDShould you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Phathom Pharmaceuticals (PHAT), ProKidney (PROK), Annexon (ANNX), Ginkgo Bioworks (DNA), Astria Therapeutics (ATXS), Humacyte (HUMA), PureTech Health (PRTC), AnaptysBio (ANAB), Mereo BioPharma Group (MREO), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry. Monopar Therapeutics vs. Phathom Pharmaceuticals ProKidney Annexon Ginkgo Bioworks Astria Therapeutics Humacyte PureTech Health AnaptysBio Mereo BioPharma Group CorMedix Monopar Therapeutics (NASDAQ:MNPR) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations, community ranking and media sentiment. Is MNPR or PHAT more profitable? Monopar Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -1,292.14%. Phathom Pharmaceuticals' return on equity of 0.00% beat Monopar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monopar TherapeuticsN/A -107.21% -87.57% Phathom Pharmaceuticals -1,292.14%N/A -79.57% Do analysts rate MNPR or PHAT? Monopar Therapeutics currently has a consensus target price of $27.33, suggesting a potential upside of 5.94%. Phathom Pharmaceuticals has a consensus target price of $23.00, suggesting a potential upside of 220.78%. Given Phathom Pharmaceuticals' higher possible upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monopar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more risk and volatility, MNPR or PHAT? Monopar Therapeutics has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Do institutionals and insiders hold more shares of MNPR or PHAT? 1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 34.9% of Monopar Therapeutics shares are held by company insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor MNPR or PHAT? Phathom Pharmaceuticals received 46 more outperform votes than Monopar Therapeutics when rated by MarketBeat users. However, 72.41% of users gave Monopar Therapeutics an outperform vote while only 72.13% of users gave Phathom Pharmaceuticals an outperform vote. CompanyUnderperformOutperformMonopar TherapeuticsOutperform Votes4272.41% Underperform Votes1627.59% Phathom PharmaceuticalsOutperform Votes8872.13% Underperform Votes3427.87% Does the media favor MNPR or PHAT? In the previous week, Phathom Pharmaceuticals had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 6 mentions for Phathom Pharmaceuticals and 3 mentions for Monopar Therapeutics. Phathom Pharmaceuticals' average media sentiment score of 0.90 beat Monopar Therapeutics' score of 0.85 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phathom Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, MNPR or PHAT? Monopar Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonopar TherapeuticsN/AN/A-$8.40M-$1.97-13.10Phathom Pharmaceuticals$26.27M18.66-$201.59M-$5.69-1.26 SummaryPhathom Pharmaceuticals beats Monopar Therapeutics on 9 of the 16 factors compared between the two stocks. Ad ProsperityPubIf you see ONE chart today… make it this one$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Goldman Sachs. This investment is driving an A.I. boom that’s being felt across many industries… Including a specific group of energy tickers since A.I. data centers use a massive amount of power. One of those tickers is CEG, up nearly 600% in the last 3 years… Combined with the upcoming presidential election, we have the recipe for a major shakeup in the market. You see, each time the U.S. elects a new president, one overlooked part of the energy sector tends to see a big move. Fact is… this energy niche is BOOMING.And expects this underappreciated niche to continue rallying well into 2026. Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNPR vs. The Competition Export to ExcelMetricMonopar TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$136.17M$6.62B$5.16B$9.09BDividend YieldN/A2.99%5.12%4.26%P/E Ratio-13.1010.6387.3217.12Price / SalesN/A195.601,157.79119.34Price / CashN/A57.1643.2337.85Price / Book13.725.114.784.77Net Income-$8.40M$151.83M$120.55M$225.50M7 Day Performance-3.37%-0.90%-1.55%-1.34%1 Month Performance28.36%-4.40%13.71%0.44%1 Year Performance1,195.83%9.17%28.65%15.39% Monopar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNPRMonopar Therapeutics1.9896 of 5 stars$25.79-0.1%$27.33+6.0%+1,195.9%$136.12MN/A-13.0910PHATPhathom Pharmaceuticals3.0076 of 5 stars$8.36+6.0%$23.00+175.1%-17.3%$571.66M$680,000.00-1.48110Gap UpPROKProKidney2.0497 of 5 stars$1.93+7.5%$4.50+133.2%-25.6%$562.91MN/A-3.553Gap UpANNXAnnexon2.1164 of 5 stars$5.16+16.2%$15.80+206.2%+30.4%$550.03MN/A-4.9060Gap DownDNAGinkgo Bioworks0.7554 of 5 stars$9.54+1.1%$4.58-52.0%N/A$548.36M$251.46M-0.721,218ATXSAstria Therapeutics2.0817 of 5 stars$9.71+2.0%$25.60+163.6%+40.8%$547.94MN/A-4.5630HUMAHumacyte3.366 of 5 stars$4.24+3.4%$13.00+206.6%+61.1%$533.64M$1.57M-3.06150Analyst ForecastGap UpPRTCPureTech Health2.0056 of 5 stars$22.20+9.1%$45.00+102.7%-20.5%$531.51M$3.33M0.00100High Trading VolumeANABAnaptysBio2.319 of 5 stars$17.02+9.2%$45.09+164.9%-29.8%$517.92M$17.16M-2.80100MREOMereo BioPharma Group2.0993 of 5 stars$3.29-12.0%$7.40+124.9%+57.3%$510.43M$1M0.0040High Trading VolumeCRMDCorMedix1.8463 of 5 stars$8.41+0.4%$15.20+80.7%+128.5%$510.29M$12.26M-10.3530 Related Companies and Tools Related Companies Phathom Pharmaceuticals Alternatives ProKidney Alternatives Annexon Alternatives Ginkgo Bioworks Alternatives Astria Therapeutics Alternatives Humacyte Alternatives PureTech Health Alternatives AnaptysBio Alternatives Mereo BioPharma Group Alternatives CorMedix Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MNPR) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
